Introduction {#s1}
============

Alternative splicing (AS) of mRNA precursors is a fundamental biological process that provides a reversible mechanism to modulate the expression of related but distinct proteins in response to internal and external stimuli ([@bib14]). Regulation of alternative splicing occurs at several levels including the expression and the targeting of specific RNA-binding proteins (RBPs). Dysregulation of alternative splicing plays a direct role in a variety of human diseases including cancer ([@bib19]).

During cancer initiation and progression, the epithelial-to-mesenchymal transition (EMT) triggers the dissociation and migration of carcinoma cells from primary to distant sites ([@bib68]). We previously demonstrated that the EMT is also tightly linked to a stem-like cell state in breast cancer, as overexpression of EMT transcription factors induces the expression of tumor-initiating cell markers and increases the ability of cells to form mammospheres, a property associated with mammary epithelial stem cells ([@bib11]; [@bib42]). In addition, the EMT has been implicated in several other cancer-related phenotypes, for example, in cancers that acquired resistance either to the EGFR inhibitor gefitinib or to the HER2 receptor inhibitor trastuzumab ([@bib6]; [@bib50]).

EMT also involves a dramatic reorganization of the actin cytoskeleton and concomitant formation of membrane protrusions to gain migratory and invasive properties ([@bib70]). The dynamic change in the actin cytoskeleton, a prerequisite for cell motility and cancer cell invasion, is a highly controlled equilibrium of local assembly and disassembly of actin filaments ([@bib70]). The filamin family proteins crosslink actin filaments and are also translocated into the nucleus to regulate the transcriptional activity of the androgen receptor and the FOXC1 transcription factor ([@bib3]; [@bib4]; [@bib39]; [@bib75]). The three members of this family (FLNA, FLNB and FLNC) are involved in both development and normal tissue homeostasis through regulating diverse processes including cell locomotion and integrin signaling ([@bib75]), and mutations in the *FLNB* gene cause a broad range of skeletal dysplasias ([@bib18]).

Alternative splicing has been previously associated with EMT. Mesenchymal cancer cells show distinct alternative splicing patterns in comparison with their epithelial counterparts ([@bib7]; [@bib51]; [@bib60]). While ESRP1 and ESRP2 are epithelial state-inducing RBPs that govern splicing patterns for the epithelial cell state ([@bib51]; [@bib62]; [@bib63]; [@bib67]), less is known about the identity and functional significance of RBPs that can promote the mesenchymal cell state. QKI and RBFOX2 have been shown to be responsible for alternative splicing events that occur during EMT, such as exon skipping in KIF13A and CTTN ([@bib7]; [@bib60]; [@bib67]) and in circular RNA formation ([@bib17]). Nevertheless, it remains unclear whether the upregulation of any specific RBPs is sufficient or required for the induction of mesenchymal state transitions or is merely one of many downstream manifestations of the EMT. Furthermore, although many splicing changes occur during EMT, only a small number of specific splicing events are known to functionally contribute to EMT including changes in the splicing of CD44, FGFR2 and Exo70 ([@bib8]; [@bib40]; [@bib63]). Here, we have undertaken a comprehensive approach to identify genes that regulate the EMT in breast cancer and found that genes whose protein products participate in AS regulate the transition to mesenchymal- and stem-like cell states.

Results {#s2}
=======

A genome scale ORF screen to identify regulators of the mesenchymal cell state {#s2-1}
------------------------------------------------------------------------------

In prior work, we described a genetically defined, experimental model of breast cancer, derived from introducing vectors expressing the telomerase catalytic subunit, the SV40 large-T and small-t antigens, and an H-Ras oncoprotein into human mammary epithelial cells (HMLER cells) ([@bib23]). Subsequent work demonstrated that the CD44 cell surface antigen is a surrogate marker for the EMT cell state change in this model ([@bib10]; [@bib11]). Thus, we separated the CD44-high and -low populations of HMLER cells by fluorescence-activated cell sorting (FACS) and confirmed that the CD44-low cells displayed epithelial properties, as measured by levels of EMT marker expression ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The highly purified CD44-low cell population remained in the epithelial cell state for at least 4 weeks in the experimental conditions. In contrast, the CD44-high HMLER cells showed elevated expression of mesenchymal markers and a greater propensity to form mammospheres, an in vitro surrogate assay for the stemness of mammary epithelial cells ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}).

To study inducers of the EMT and stem-like cell state, we performed a genome scale open-reading frame (ORF) screen to identify genes that convert the HMLER cells from the CD44-low state to the CD44-high state. Each ORF in the human ORFeome library collection 8.1 ([@bib66]) was tagged with a unique 24-nucleotide barcode and introduced into FACS purified CD44-low HMLER cells by lentiviral-mediated gene transfer. Following 7 days in culture, we purified the newly arising CD44-high HMLER cells by FACS and identified ORFs enriched in these cells by massively parallel sequencing ([Figure 1A](#fig1){ref-type="fig"}).

![Genome scale ORF screen identifies splicing factors and RNA-binding proteins as regulators of EMT.\
(**A**) Schematic of the genome scale ORF screen used to identify regulators of EMT. (**B**) Distribution of enrichment Z scores. The red dots indicate the ORFs with a Z score \>3 and the top 15 gene names are labeled ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). (**C**) The top candidate ORFs in the screen categorized into seven different functional classes. (**D**) Network analysis of enriched protein complexes among the top candidates ORFs. (**E**) GO term enrichment analysis of the top candidate ORFs. (**F**) Enrichment for RNA metabolic processes among the top candidate ORFs, as determined by pre-ranked GSEA analysis.\
10.7554/eLife.37184.006Figure 1---source data 1.ORF screen results.](elife-37184-fig1){#fig1}

We found that the consistency between the biological replicates of the screen was high ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). *SNAI1*, a well-characterized EMT-inducing transcription factor (EMT-TF) ([@bib44]), scored as the top hit in the screen, as did *BCL6*, *JMJD6* and *FOS*, which have previously been shown to play key roles in regulating EMT ([@bib1]; [@bib22]; [@bib71]) ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}); these findings indicated that this screen was robust. We used a cut-off of three standard deviations (S.D.) above the mean and analyzed the top-scoring candidates to identify protein complexes or pathways enriched for regulators of EMT. Sixty-eight ORFs met this criterion ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), including transcription factors, RNA splicing factors, kinases and phosphatases, epigenetic regulators, and genes involved in the regulation of spermatogenesis, apoptosis and the metabolic processing of cellular amides ([Figure 1C](#fig1){ref-type="fig"}). Other EMT transcription factors did not meet the 3 S.D. cutoff possibly due to mutations in the ORF constructs or low ORF representation in the library.

Using the GeNets analysis tool (*apps.broadinstitute.org/genets*), we found three gene networks centered around *QKI* (Quaking, an RNA-binding protein), *SRPK2* (a kinase involved in RNA splicing) and *PPP1CC* (a phosphatase) ([Figure 1D](#fig1){ref-type="fig"}). When we used the top candidates to interrogate gene ontology, we found that the 'regulation of mRNA metabolic process' and 'regulation of mRNA splicing, via spliceosome' scored as the top terms ([Figure 1E](#fig1){ref-type="fig"}) and that 'RNA metabolic process' was one of the top gene sets enriched by gene set enrichment analysis (GSEA) ([Figure 1F](#fig1){ref-type="fig"}) ([@bib48]). Of note, 'Regulation of mRNA metabolic process' is a parent GO term for RNA processing and RNA splicing.

Several RNA-binding proteins have been previously associated with EMT. For example, ESRP1 and 2 promote an epithelial phenotype, while QKI and RBFOX2 (a homolog of RBFOX1 that scored in the screen) regulate a number of EMT-associated splicing events ([@bib7]; [@bib60]; [@bib67]). Of note, although RBFOX2 has been shown to play a role in EMT ([@bib7]; [@bib60]), the RBFOX2 clone present in the ORFeome collection 8.1 library harbors three mutations (a 396--449 deletion, a 752--763 deletion and a C to T substitution at 1007), which likely explained why this ORF did not score in the screen. However, whether the expression of any RBPs is functionally sufficient or required to induce a mesenchymal cell state remains unclear. Since we found a striking enrichment of RBPs in this screen, we focused on the top candidates implicated in pre-mRNA splicing to understand their possible role in regulating the EMT and stem-like cell states in breast cancer pathogenesis.

Expression of QKI and RBFOX1 are necessary and sufficient to induce an intermediate mesenchymal cell state {#s2-2}
----------------------------------------------------------------------------------------------------------

In the ORF expression screen, we identified eight candidate RBPs (QKI, RBFOX1, MBNL1, MBNL2, CELF4, SFPQ, SRSF9 and HNRNPUL1) that scored when tested individually. We systematically tested these genes in five assays to examine EMT-associated phenotypes or marker expression to find the RBPs that meet the following criteria: (1) Expression of the RBP promotes an increase in the CD44-high population ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}); (2) Expression of the RBP upregulates the expression of a panel of mesenchymal markers examined by both quantitative PCR ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) and immunoblotting ([Figure 2B](#fig2){ref-type="fig"}); (3) Expression of the RBP induces mammosphere formation when cells are grown in suspension, a characteristic of the stem-like and mesenchymal cell properties ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}) ([@bib11]; [@bib42]); (4) Endogenous expression of the RBP is upregulated upon overexpression of an EMT-inducing transcription factor, SNAI1 or ZEB1 ([Figure 2---figure supplement 2A--D](#fig2s2){ref-type="fig"}); (5) Expression of the RBP promotes tumor formation in vivo, a feature associated with stem-like cells ([Figure 2D](#fig2){ref-type="fig"} and[Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}) ([@bib11]; [@bib42]). Together, we discovered that the expression of QKI (NCBI Reference: NM_006775.2, also known as QKI-5) and RBFOX1 (NCBI Reference: NM_145893.2, also known as RBFOX1 beta) strongly induced the mesenchymal and stem-like phenotypes in all the experiments tested, while MBNL1, MBNL2 and CELF4 scored in some assays. We also found that SRSF9, SFPQ and HNRNPUL1 are unlikely to initiate a mesenchymal and stem-like cell state ([Figure 2J](#fig2){ref-type="fig"}). The CD44-high cells induced by QKI, RBFOX1 or SNAI1 shared a similar elongated and spindle shape cell morphology ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). In addition, QKI and RBFOX1 overexpression also significantly increased the CD44-high cell populations in two additional breast cancer cell lines (MCF7 and ZR75-1) ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}). We thus proceeded to focus on the role of QKI and RBFOX1 in EMT.

![QKI and RBFOX1 are sufficient and partially required for an intermediate mesenchymal and stem-like cell state.\
(**A**) Heatmap showing the expression of mesenchymal (FN1, VIM, ZEB1) and epithelial (CDH1, KRT14) markers in HME cells expressing the indicated candidate ORFs, normalized to a negative control (EGFP) and quantified by qPCR. n = 3. Bar graphs and statistical significance for each gene are shown in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}. (**B**) Levels of EMT marker expression in HME cells expressing the indicated candidate ORFs quantified by immunoblotting. (**C**) The rate of mammosphere formation in HMLE cells that express the indicated ORFs. The number of mammosphere per 1000 cells plated was counted. n = 5, \*\*\*, p\<0.001; \*\*, p\<0.01; \*, p\<0.05. Representative images are shown in [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}. (**D**) In vivo tumor formation assay. HMLER cells expressing the corresponding ORFs were injected subcutaneously into immuno-compromised mice and tumor growth was monitored for 15 weeks. Shown are an image of tumor sizes (left) and quantification of tumor weights (right) (individual tumor growth curves are shown in [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). n = 9, \*\*, p\<0.01; \*, p\<0.05, Student's two-tailed t-test. (**E**) The percentage of CD44-high cells when SNAI1 is overexpressed along with shRNAs targeting candidate RNA-binding proteins or LacZ as a negative control. The red bar indicates a positive control shRNA against SNAI1 and the orange bars indicate shRNAs targeting *QKI* and *RBFOX1*. The knockdown efficiency is shown in [Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}. n = 4, \*\*\*, p\<0.001; \*\*, p\<0.01; \*, p\<0.05, Student's two-tailed t-test. (**F--I**) The effect of CRISPR/Cas9-targeting of endogenous QKI or RBFOX1 in HMLE cells ectopically expressing SNAI1 on: (**F**) the percentage of CD44-high cells, (**G**) EMT marker expression (VIM: mesenchymal marker, CDH1: epithelial marker) quantified by qPCR, (**H**) EMT marker expression quantified by immunoblotting and (**I**) mammosphere formation. Also shown is the efficiency of gene knockout as quantified by immunoblotting. (**B**) n = 4, (**C**) n = 4, (**E**) n = 3, \*\*\*, p\<0.001; \*\*, p\<0.01; \*, p\<0.05, Student's two-tailed t-test. (**J**) Summary of effects of ORFs on EMT markers and phenotypes.](elife-37184-fig2){#fig2}

Of note, overexpression of QKI and RBFOX1 reduced cell proliferation by 40% to 45% as would be expected if the cells undergo an EMT ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}) ([@bib56]; [@bib59]). In addition, the expression of QKI, RBFOX1 and other RBPs failed to decrease the expression of epithelial markers ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), suggesting that the cell state triggered by expression of the RBPs involves elevated expression of mesenchymal markers with retention of pre-existing epithelial marker expression. This spectrum of marker expression is reminiscent of an intermediate EMT state that is implicated in development and tumor progression ([@bib5]; [@bib26]; [@bib44]; [@bib49]).

To determine whether expression of QKI or RBFOX1 was also required for the induction of an EMT program, we silenced endogenous QKI or RBFOX1 by short hairpin RNA (shRNA)-mediated suppression and by CRISPR/Cas9-mediated knockout. First, we expressed the SNAI1 EMT-TF to induce EMT and then depleted QKI, RBFOX1 or other candidate RBPs with shRNAs (shSNAI1 as a positive control) ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). shRNA-mediated suppression of QKI and RBFOX1 led to a significant reduction in the CD44-high cell population ([Figure 2E](#fig2){ref-type="fig"}), suggesting that the expression of QKI and RBFOX1 was partially required for the induction of the CD44-high cell population after SNAI1 overexpression. To eliminate the potential off-target effects of the shRNAs, we used CRISPR/Cas9 to target the QKI and RBFOX1 genes and found that the ablation of QKI and RBFOX1 also significantly suppressed the induction of CD44-high cells ([Figure 2F](#fig2){ref-type="fig"}), the expression of mesenchymal markers ([Figure 2G,H](#fig2){ref-type="fig"}) and the formation of mammospheres ([Figure 2I](#fig2){ref-type="fig"}) after SNAI1 overexpression. Thus, these loss-of-function studies revealed that QKI and RBFOX1 are partially required for induction of the EMT.

We next examined whether the expression of QKI and RBFOX1 also correlated with mesenchymal features in murine or human tumor samples. We discovered that the expression of QKI was highly upregulated in mesenchymal breast tumor patient samples available from the Cancer Genome Atlas (TCGA) ([@bib15]) ([@bib12]) ([Figure 2---figure supplement 4A](#fig2s4){ref-type="fig"} and the Materials and methods section for data analysis). The lack of a significant change in expression of RBFOX1 suggested that QKI instead may play a major role in driving the alternative splicing patterns in these samples. In addition, both Qk and Rbfox1 are highly associated with the activation of an EMT program in a murine mammary tumor model ([Figure 2---figure supplement 4B--D](#fig2s4){ref-type="fig"} and the Materials and methods section) ([@bib27]).

Collectively, although QKI has been previously associated with AS changes occurring during EMT, our observations demonstrate that overexpression of QKI or RBFOX1 suffices to promote an intermediate mesenchymal and stem-like cell state and are also necessary for the SNAI1-induced EMT. Further, the expression of endogenous QKI and RBFOX1 were also induced by EMT-TFs such as SNAI1 or ZEB1 ([Figure 2J](#fig2){ref-type="fig"}). These results extend prior observations implicating these RNA binding proteins in EMT and confirm that our screen identified key regulators of EMT.

Characterizing alternatively spliced transcripts that are regulated by QKI and RBFOX1 {#s2-3}
-------------------------------------------------------------------------------------

Although QKI and RBFOX2 (a homolog of RBFOX1) have been shown to regulate AS events during EMT ([@bib7]; [@bib60]; [@bib67]), it remains unclear whether QKI and RBFOX1 alter splicing of genes directly involved in EMT or if the expression of these RNA binding proteins merely correlate with the mesenchymal cell state. To dissect the mechanism by which QKI and RBFOX1 induce the intermediate mesenchymal and stem-like cell states, we overexpressed each of these or a control protein (hcRED or EGFP) in HME cells and used RNA-sequencing to assess changes in transcriptional programs. We subsequently used replicate multivariate analysis of transcript splicing (rMATS) to individually quantify and analyze differences in AS events in HME cells expressing either the hcRED or EGFP control proteins versus QKI, RBFOX1 or SNAI1 ([@bib52]). Indeed, HME cells that expressed QKI or RBFOX1 exhibited a \> 5 fold increase in the number of alternatively spliced events compared to control cells that expressed hcRED ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} and [Figure 3---source datas 1](#fig3sdata1){ref-type="supplementary-material"} and [2](#fig3sdata2){ref-type="supplementary-material"}). Among all detected types of splicing events, the majority of splicing changes after overexpression of QKI or RBFOX1 occurred in skipped exons ([Figure 3A](#fig3){ref-type="fig"}). We next used pre-ranked GSEA to analyze the pathways that are regulated by QKI or RBFOX1 and found that their downstream splicing targets were enriched in gene modules involved in cell motility/cytoskeleton organization, stem cell fate determination, oncogenic signaling and epigenetic targets ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}).

![Identification of splicing targets regulated by QKI and RBFOX1.\
(**A**) Quantification of the different types of alternative splicing events regulated by QKI or RBFOX1 overexpression as determined using rMATS. Exclusion or inclusion are relative to control cells overexpressing EGFP. (**B**) RT-PCR validation of individual splicing events regulated by QKI or RBFOX1. The cDNA from cells expressing the indicated ORFs were subjected to PCR amplification using primers flanking the alternative exon. The ratios of the intensity of the upper (inclusion) and lower (exclusion) PCR product bands were quantified and the relative intensity of the upper band is indicated. Below are shown RNA-sequencing based quantification of the % inclusion of the alternative exon. n = 3 (EGFP, HcRed and RBFOX1) or n = 2 (QKI and SNAI1).\
10.7554/eLife.37184.014Figure 3---source data 1.QKI rMATS splicing output.\
10.7554/eLife.37184.015Figure 3---source data 2.RBFOX1 rMATS splicing output.](elife-37184-fig3){#fig3}

We then individually validated the top alternatively spliced genes regulated by both QKI and RBFOX1 with the hypothesis that shared targets were more likely to be involved in EMT. We focused on the genes with alternatively skipped exons, as it is the most prevalent type of AS in higher eukaryotes ([@bib33]). We confirmed that, consistent with the RNA-seq results, pre-mRNAs of specific exons in the genes involved in cell motility/cytoskeleton organization, *FLNB, SLK, NUMB, CA12*, *ESYT2* and *ATP5C1* showed substantially greater skipping in cells expressing QKI and RBFOX1, as compared to control cells expressing hcRED or EGFP ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, the same AS pattern for these genes was also observed in mesenchymal HME cells overexpressing SNAI1, indicating that the AS events observed in SNAI1-expressing cells are likely to be due to the activity of QKI and RBFOX1.

QKI and RBFOX1 regulate the alternative splicing of FLNB {#s2-4}
--------------------------------------------------------

From our RNA-sequencing analysis, we found that many AS events, and in particular, skipped exons, were regulated by both QKI and RBFOX1 ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). To identify direct targets of QKI and RBFOX1, we performed enhanced UV crosslinking and immunoprecipitation followed by sequencing (eCLIP-seq) in HME cells ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}) ([@bib58]). QKI-binding sites were located predominantly in introns, while the majority of RBFOX1-binding sites were found both in introns and 3'UTRs, and consistent with prior studies. We also recovered the known QKI (ACUAAC) and RBFOX1 (UGCAUG) binding motifs ([Figure 4B,C](#fig4){ref-type="fig"}). Interestingly, we found that QKI-binding sites were also highly enriched for the RBFOX-binding motif, UGCAUG ([Figure 4B,C](#fig4){ref-type="fig"}) and overall, there was a substantial degree of overlap between QKI and RBFOX1 eCLIP-binding peaks (p\<0.001, [Figure 4D](#fig4){ref-type="fig"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). When examining the 183 exon skipping events that we found to be regulated by both QKI and RBFOX1, we detected binding sites for both QKI and RBFOX1 for 36 events, with peaks overlapping the exon itself or positioned in the flanking introns ([Figure 4E](#fig4){ref-type="fig"}). Since the QKI and RBFOX1 proteins have previously been shown to physically associate with one another ([@bib37]), we then tested whether these two proteins were also interacting in HME cells. When we isolated endogenous QKI complexes by immunoprecipitation, we detected a robust interaction with RBFOX1 protein that did not require the presence of RNA ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Thus, these observations demonstrate that QKI and RBFOX1 interact in human mammary epithelial cells and suggest that they concurrently bind to and regulate the AS of common downstream targets.

![QKI and RBFOX1 cooperatively regulate the alternative splicing of common downstream targets, including FLNB.\
(**A**) Venn diagram illustrating the overlap in skipped exons regulated by QKI and RBFOX1, as detected by RNA-seq. The significance of overlap was determined by Fisher's exact test. (**B, C**) Binding distributions and de novo motifs identified from eCLIP-seq analysis of significant peaks (p≤10^−5^, fold-enrichment ≥8). The QKI (**B**) or RBFOX1 (**C**) binding distributions are shown in pie charts (upper). Below are shown the top two ranked QKI (**B**) and RBFOX1 (**C**) binding motifs. (**D**) Venn diagram illustrating the overlap in binding peaks detected by eCLIP-seq analysis of QKI and RBFOX1. p\<0.001, as determined by random shuffling of one set of peaks and repeated testing of the extent of overlap. (**E**) Percentage of SE splicing events regulated by both QKI and RBFOX1 (n = 183), that contain CLIP-binding peaks located in the exon or flanking introns, for either or both proteins. (**F**) Heatmap depicting the association between an EMT signature score (top row) and AS events in a panel of breast cancer cell lines. Shown are the top 20 AS events that are positive or negatively associated with the EMT score. (**G**) Scatter plot of the change in 'Percentage Spliced In' (PSI) for SE events shared between QKI and RBFOX1. ΔPSI values are for each ORF relative to EGFP. Colored dots indicate events in CD44 or FLNB. (**H**) Tracks indicate eCLIP-seq read density for QKI and RBFOX1 at FLNB exon 30, normalized to a million total usable reads. Below each pair of replicate tracks are shown significant binding peaks called by CLIPper software (p≤10^−5^, fold-enrichment ≥8). Also shown are size-matched input controls for each pair of replicates.\
10.7554/eLife.37184.018Figure 4---source data 1.QKI and RBFOX1 overlapping events.\
10.7554/eLife.37184.019Figure 4---source data 2.QKI and RBFOX1 CLIP peaks.](elife-37184-fig4){#fig4}

To identify transcripts whose AS is likely to play a functional role in promoting EMT, we assessed which QKI and RBFOX1-regulated AS events were also associated with an EMT gene signature across a panel of breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) ([@bib2]). We examined the AS events in breast cancer cell lines that were ranked by their EMT gene signature score ([@bib9]), using the *Information Coefficient* (IC), an information-theoretic measure ([@bib34]), and an empirical permutation test for statistical significance of the top hits ([@bib2]). Among all the common targets of QKI and RBFOX1, we found that *CD44* (IC:0.857, p value:\<6.59e-07) and *FLNB* (IC:0.848, p value:\<6.59e-07) scored as the top two genes that most strongly associated with the EMT signature in breast cancer cell lines ([Figure 4F](#fig4){ref-type="fig"}). *CD44* and *FLNB* were also among the top genes regulated by both QKI and RBFOX1 in HME cells ([Figure 4G](#fig4){ref-type="fig"}). Prior work has demonstrated that AS of CD44 to produce the standard shorter isoform promoting EMT, and that CD44 splicing is not only a marker of the EMT state but also contributes to EMT ([@bib8]). However, the functional importance of FLNB in EMT has not yet been characterized. Exon 30 of FLNB is skipped when QKI and RBFOX1 are overexpressed ([Figure 3B](#fig3){ref-type="fig"}), and we found that both QKI and RBFOX1 were strongly bound to the intron flanking this exon ([Figure 4H](#fig4){ref-type="fig"}, QKI peak p value = 2.2e-16; RBFOX1 peaks p value = 3.0e-7 and 1.8e-9). Although RBFOX1-binding downstream of an exon typically results in splicing enhancement ([@bib16]), we found that binding of RBFOX1 downstream of FLNB exon 30 instead results in splicing repression. Together these observations support the view that QKI and RBFOX1 coordinately regulate the AS of genes associated with EMT.

Alternative splicing of FLNB is strongly associated with basal-like breast cancer {#s2-5}
---------------------------------------------------------------------------------

Based on gene expression analysis, prior studies stratified breast cancer cell lines into basal B, basal A and luminal clusters, among which, the basal B subtype expresses mesenchymal markers and displays a high degree of stem-like cell features ([@bib32]; [@bib43]). To identify the alternative transcripts that correlated with the basal B subtype of breast cancer, we analyzed alternatively spliced events in breast cancer cell lines included in the CCLE ([@bib2]). We found several targets of QKI and RBFOX1, including *FLNB*, *SLK*, *USO1*, *ENAH*, *ESYT2*, *NUMB* and *ARHGEF1*, to be among the most differentially spliced genes in basal B breast cancer cell lines ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Strikingly, we observed a bimodal distribution for the AS of FLNB ([Figure 5A](#fig5){ref-type="fig"}), in which the shorter mesenchymal FLNB isoform corresponding to a lower exon 30 \'Percent Spliced In\' (PSI) value, occurred overwhelmingly in basal B cell lines, while the longer epithelial FLNB isoform existed predominantly in luminal and basal A cell lines. We validated this finding in two basal B (BT549 and MDAMB231) and two luminal (ZR75-1 and MCF7) cell lines by RT-PCR ([Figure 5A](#fig5){ref-type="fig"}).

![Alternative splicing of FLNB exon 30 is strongly associated with basal-like breast cancer.\
(**A**) FLNB exon 30 PSI in all CCLE breast cancer cell lines. RT-PCR validation of FLNB exon 30 splicing in two Basal B cell lines (BT549 and MDAMB231) and two luminal cell lines (ZR75-1 and MCF7) is shown on the right. (**B**) CCLE cell lines (except hematopoietic cell lines, n = 787) were ranked by their FLNB exon 30 Percent Spliced In (PSI) values, and associated gene expression signatures were analyzed by the REVEALER program. The top associated signatures with their Information coefficient (IC), p values and False Discovery Rates (FDR) are shown.](elife-37184-fig5){#fig5}

We further found that there is a strong association between the AS of FLNB exon 30 and EMT gene expression features in breast cancer cell lines ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). When we examined all non-hematopoietic cancer cell lines in the CCLE, we found that the degree of FLNB exon 30 splicing correlated significantly with a ZEB1 target signature, an epithelial differentiation signature, two metastasis signatures and a mammary stem cell signature ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). These observations further confirmed that the AS of FLNB exon 30 strongly associates with EMT and a stem-like cell state. In addition, the strong association between FLNB splicing and EMT features suggest that FLNB exon 30 splicing may serve as a biomarker for residence of cancer cells in a mesenchymal state.

Since mesenchymal and stem-like cell features are enriched in basal-like breast cancer, we examined whether the splicing of FLNB and the expression of QKI or RBFOX1 were associated with the basal-like subtype in TCGA Breast Invasive Carcinoma (BRCA) samples. We observed lower expression of the longer FLNB isoform with exon 30 included and higher expression of the shorter FLNB isoform in samples classified as the basal subtype, consistent with the notion that FLNB splicing plays a role in regulating the mesenchymal and stem-like cell state ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Similarly, we discovered elevated expression of QKI (NM_006775, also called QKI-5) in basal-like breast cancers relative to other subtypes of breast cancers ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}).

FLNB isoform switching promotes a mesenchymal-like cell state {#s2-6}
-------------------------------------------------------------

FLNB is a member of the Filamin family of actin-binding proteins (FLNA, B and C). Prior work has implicated the role of filamins in actin crosslinking, focal adhesion kinase and integrin signaling, and regulating transcriptional activity ([@bib24]; [@bib57]; [@bib65]; [@bib75]). Filamins share an N-terminal actin-binding domain, two hinge regions, and 24 filamin-type immunoglobulin-like (FLN) domains that are involved in the formation of tail-to-tail dimers ([@bib24]; [@bib57]). Exon 30 of FLNB encodes the first hinge (H1) domain, which governs filamin protein flexibility and calpain cleavage sensitivity ([Figure 6A](#fig6){ref-type="fig"}) ([@bib24]; [@bib65]). The skipping of exon 30 results in loss of the H1 domain from the full-length protein without altering the remainder of the protein. Hereafter, we refer to the longer isoform of FLNB (including exon 30) as FLNB-L, and to the shorter isoform (which lacks exon 30) as FLNB-ΔH1. When we tested whether the splicing of FLNB differed between the CD44-high and CD44-low cell populations ([Figure 6B](#fig6){ref-type="fig"}), we found that FLNB exon 30 skipping occurred exclusively in the CD44-high mesenchymal and stem-like cell population.

![FLNB isoform switching promotes the mesenchymal cell state.\
(**A**) Schematic of FLNB (Filamin B) protein domain structure, which contains an N-terminal actin-binding domain (ABD, shown in yellow), 24 filamin repeats (shown in blue) and two hinge domains (H1 and H2, shown in red). The exon 30 of FLNB encodes the first hinge domain (**H1**). (**B**) CD44-high and CD44-low HMLER cells were sorted and FLNB AS was analyzed by RT-PCR with primers flanking FLNB exon 30. The CD44-high HMLER cells were spontaneously generated. (**C**) The expression of FLNB was suppressed by siRNAs against FLNB 3'UTR region (FLNB-U1, U2 and UTR1,2) in HMLE cells. FLNB-U1,2 is a pool of FLNB-U1 and FLNB-U2 siRNAs. Protein levels of FN1, VIM (mesenchymal markers), CDH1 (epithelial marker) and FLNB after FLNB suppression was quantified by immunoblotting. (**D**) The expression of FLNB was rescued by FLNB-L (FLNB long isoform) or FLNB-ΔH1 (FLNB lacking H1 domain) after endogenous FLNB depletion by siRNA targeting the UTR of FLNB (FLNB-U1,2). Protein levels of FN1, VIM (mesenchymal markers), CDH1 (epithelial marker) and FLNB were quantified by immunoblotting. (**E**) Schematic of CRISPR/Cas9-mediated targeting of the FLNB intron 29 - exon 30 junction. (Left) Guide RNAs were designed to target the junction of FLNB intron 29 (in lower-case black letters) and exon 30 (in capital red letters). (Right) Examples of modifications to the junction induced by sgRNAs sgFLNB-SK2 and sgFLNB-SK4 are shown. (**F**) FLNB exon 30 skipping and total FLNB levels were quantified in cells expressing sgRNAs targeting the junction of FLNB intron 29 and exon 30 by RT-PCR (upper) and immunoblot (lower) (corresponding to [Figure 6E](#fig6){ref-type="fig"}). (**G--I**) Effect of CRISPR/Cas9-mediated modulation of the FLNB-L/FLNB-ΔH1 ratio on the expression of mesenchymal and epithelial markers as examined by qPCR (**G**), on the expression of CD44 as analyzed by flow cytometry (**H**), and on the number of mammosphere formed per 1000 cells cultured in low attachment condition (**I**). n = 4 for (**G**), n = 6 for (**H**), n = 3 for (**I**). \*, p\<0.05; \*\*, p\<0.01, Student's two-tailed t-test compared to sgGFP controls.](elife-37184-fig6){#fig6}

To investigate the function of FLNB in regulating EMT, we suppressed FLNB expression using siRNAs targeting the *FLNB* 3'UTR region in HMLE cells, in which the FLNB-L isoform represents the majority of FLNB protein. We found that suppression of FLNB-L upregulated the expression of mesenchymal markers, VIM and FN1, indicating that FLNB-L plays a negative role in regulating EMT ([Figure 6C](#fig6){ref-type="fig"}). To dissect the respective role of FLNB-L and FLNB-ΔH1 isoforms, we rescued the suppression of endogenous FLNB by ectopically expressing each isoform of FLNB ([Figure 6D](#fig6){ref-type="fig"}). Depletion of FLNB promoted the expression of mesenchymal markers. We found that FLNB-L reduced the expression of mesenchymal markers, FN1 and VIM. In contrast, the expression of FLNB-ΔH1 did not decrease the mesenchymal marker expression. When the two isoforms of FLNB were expressed in a mesenchymal cell line, MDA-MB-231, we also found that FLNB-L overexpression suppressed mesenchymal marker expression, strongly suggesting that FLNB-L inhibits the EMT ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Interestingly, when we expressed each isoform in HMLE cells in the presence of the endogenous FLNB-L, FLNB-ΔH1 ectopic expression elevated mesenchymal markers while the expression of FLNB-L did not significantly alter expression of the same set of markers ([Figure 6---figure supplement 1B,C](#fig6s1){ref-type="fig"}). Since filamin proteins dimerize ([@bib4]; [@bib47]; [@bib53]), the effects of FLNB-ΔH1 proteins likely represent interactions with the endogenous FLNB-L, which blocks the suppressive effect mediated by FLNB-L. As before, we did not observe robust changes in the expression of pre-existing epithelial markers in these experiments, reminiscent of our previous observation that QKI or RBFOX1 induces an intermediate mesenchymal state with retention of epithelial markers and acquisition of mesenchymal ones ([Figure 2A,B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Together, these results support the view that the skipping of the exon 30 of FLNB switches the function of the FLNB from suppressing to promoting the EMT.

To manipulate the ratio of the two FLNB isoforms and dissect the function of the FLNB exon 30 skipping, we modified the genomic locus of the intron-exon junction using CRISPR/Cas9-mediated genome editing to skew the isoform ratio of the endogenous FLNB transcripts. We designed several sgRNAs that target the junction of intron 29 and exon 30 (sgFLNB-SK2 and SK4). Remarkably, we found that disrupting this junction in the genomic locus was effective in causing skipping of the endogenous exon 30 of FLNB ([Figure 6E,F](#fig6){ref-type="fig"}). In line with our previous observations, FLNB exon 30 skipping induced by this approach also increased the expression of mesenchymal markers ([Figure 6G](#fig6){ref-type="fig"}). We also discovered that FLNB exon 30 skipping induced a modest but significant increase in the CD44-high cell population and in the number of mammospheres under low attachment growth conditions ([Figure 6H,I](#fig6){ref-type="fig"}).

In addition, we used two sets of siRNAs that targeted either exon 30, or the junction between exon 29 and exon 31 when exon 30 is skipped. The siRNAs that target the exon 29--31 junction selectively disrupt formation of the FLNB-ΔH1 isoform, since the FLNB-L isoform lacks the siRNA target sequences. This approach effectively altered the ratio of FLNB-L and FLNB-ΔH1 ([Figure 6---figure supplement 1D,E](#fig6s1){ref-type="fig"}) and revealed that an elevated ratio of the FLNB-ΔH1 isoform over the FLNB-L isoform and a reduction of FLNB protein levels significantly increased the level of mesenchymal markers, consistent with the effect of ectopically expressing FLNB-ΔH1 or CRISPR/Cas9-mediated editing of the splice junction ([Figure 6C--I](#fig6){ref-type="fig"}). Together, these observations demonstrate that the skipping of FLNB exon 30 contributes to the acquisition of a mesenchymal-like cell state.

EMT mediated by FLNB exon 30 skipping is dependent on the FOXC1 transcription factor {#s2-7}
------------------------------------------------------------------------------------

In addition to their function in the cytoplasm, actin-binding proteins, such as the Filamin family, have been shown to localize to the nucleus and regulate transcription and gene expression ([@bib3]; [@bib4]; [@bib45]; [@bib74]; [@bib75]). We tested whether the two isoforms of FLNB generated by alternative splicing of exon 30 localized to different subcellular compartments. By comparing HMLE cells expressing a control sgRNA targeting GFP (sgGFP) or sgRNAs that induce exon 30 skipping (sgFLNB-SK2 and SK4) ([Figure 6E](#fig6){ref-type="fig"}), we found that the FLNB-L isoform localized to both the cytoplasm and the nucleus while FLNB-ΔH1 was preferentially localized to the cytoplasm (50% reduction in nuclear localization, [Figure 7A](#fig7){ref-type="fig"}). We confirmed this change of FLNB localization using immunofluorescence ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Thus, alternative splicing of exon 30 changes the nuclear localization of FLNB.

![EMT mediated by FLNB isoform switching is dependent on the FOXC1 transcription factor.\
(**A**) Analysis of nuclear and cytoplasmic fractions of FLNB. HMLE cells expressing Cas9 and sgRNAs targeting GFP (sgGFP, as control) or targeting the FLNB intron 29 - exon 30 junction to induce exon skipping (sgFLNB-SK2 and SK4, described in [Figure 6E](#fig6){ref-type="fig"}), were subjected to subcellular fractionation. The levels of FLNB proteins in the nuclear and cytoplasmic fractions were analyzed by immunoblotting and the skipping of exon 30 was confirmed by RT-PCR. The nuclear levels of FLNB is diminished when exon 30 is skipped. (**B**) Interaction between FLNB, FOXC1 and PBX1 in the nucleus as determined by immunoprecipitation followed by immunoblotting. HMLE cells expressing Cas9 and sgRNAs targeting GFP (sgGFP, as control) or targeting the FLNB intron 29 - exon 30 junction to induce exon skipping (sgFLNB-SK4, described in [Figure 6E](#fig6){ref-type="fig"}), were subjected to immunoprecipitation analysis using nuclear protein extract. The interaction between FLNB and FOXC1 in the nuclear extract was reduced largely due to the decrease in nuclear FLNB levels. (**C**) The depletion of FOXC1 diminishes the upregulation of mesenchymal markers (ZEB1 and FN1) mediated by FLNB exon 30 skipping (sgFLNB-SK2 and SK4, shown in red bars) as measured by qPCR. n = 6, \*, p\<0.05; \*\*, p\<0.01, Student's two-tailed t-test. The knockdown efficiency for FOXC1 is shown in the upper panel. (**D**) The rate of mammosphere formation in HMLE cells that expressed the indicated sgRNAs and transfected with a FOXC1 siRNA pool. The number of mammospheres per 1000 cells plated was counted. Representative images (left) and quantification (right) are shown. n = 3, \*\*, p\<0.01, Student's two-tailed t-test. (**E, F**) Depletion of FOXC1 diminishes the upregulation of mesenchymal markers (**E**) and mammosphere formation (**F**) mediated by QKI and RBFOX1 expression, as measured by qPCR (**E**) and mammosphere formation assay (**F**). n = 6 for (**E**), n = 4 for (**F**). \*, p\<0.05; \*\*, p\<0.01, Student's two-tailed t-test. (**G**) A model of the mechanism underlying the QKI and RBFOX1-induced mesenchymal and stem-like cell state.](elife-37184-fig7){#fig7}

Filamin A has been reported to assemble a protein complex with FOXC1 and PBX1, which inhibits FOXC1 transcriptional activity ([@bib4]; [@bib74]; [@bib75]). To test whether Filamin B also forms a complex with FOXC1 in HMLE cells, we confirmed that FLNB interacts with FOXC1 by co-immunoprecipitation ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Furthermore, we found that the interaction among FLNB, FOXC1 and PBX1 was reduced when we induced FLNB exon 30 skipping, largely due to the decreased amount of nuclear FLNB protein ([Figure 7B](#fig7){ref-type="fig"}). Based on these observations, we conclude that FLNB nuclear exclusion, mediated by exon 30 skipping, regulates its interaction with FOXC1.

FOXC1 is a transcription factor that induces EMT ([@bib29]; [@bib31]; [@bib46]; [@bib76]). Since the nuclear filamins inhibit FOXC1 activity ([@bib4]; [@bib74]; [@bib75]), we hypothesized that the reduced nuclear localization of FLNB promotes EMT by releasing FOXC1 from FLNB. Specifically, we tested whether the EMT induced by FLNB isoform switching was dependent on FOXC1. Indeed, we found that FOXC1 depletion by siRNA significantly dampened the upregulation of mesenchymal marker expression ([Figure 7C](#fig7){ref-type="fig"}) and the formation of mammospheres ([Figure 7D](#fig7){ref-type="fig"}) mediated by FLNB exon 30 skipping. Furthermore, we found that FOXC1 is also partially required for the upregulation of mesenchymal marker expression ([Figure 7E](#fig7){ref-type="fig"}) and increase in mammosphere formation ([Figure 7F](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) induced by QKI and RBFOX1 expression, which regulate the alternative splicing of FLNB exon 30. In summary, the skipping of FLNB exon 30 promotes EMT by reducing FLNB nuclear localization and release of the FOXC1 transcription factor.

Discussion {#s3}
==========

Splicing is a key step in the regulation of almost all human transcripts. The recent genomic characterization of cancers has revealed recurrent somatic mutations and copy number alterations in RNA splicing factors and RBPs in a significant subset of human tumors ([@bib21]). Cancer cells harboring aberrant splicing factor expression or mutations in genes encoding splicing factors display unique cancer-specific mis-splicing that may facilitate tumor formation and progression. Although alternative splicing has been associated with EMT previously, in-depth studies are needed to better understand the mesenchymal cell state-specific RBPs and their functional downstream targets. Here, we found that QKI and RBFOX1 regulate the splicing of an exon in the actin-binding protein FLNB to regulate the EMT in breast cancer. This finding suggests that the AS of a single exon may serve as a highly quantifiable surrogate molecular biomarker for the process of EMT in solid tumors.

Recent work has shown that cells often progress through a spectrum of intermediate states between the fully epithelial and fully mesenchymal cell phenotypes ([@bib26]; [@bib44]). We found that the mesenchymal cell state mediated by the expression of QKI and RBFOX1 exhibited upregulation of mesenchymal markers with continued retention of certain epithelial markers, indicating that this cell state is one that lies in-between the fully epithelial and fully mesenchymal poles of this spectrum. Consistent with prior studies ([@bib44]; [@bib49]), our results suggest that the intermediate/partial mesenchymal cell state displays a high degree of stem cell features and fosters tumor formation in vivo.

The control of AS by RNA-binding proteins is highly context dependent ([@bib25]) and tissue specific ([@bib69]). QKI has been shown to be a tumor suppressor in brain tumors ([@bib13]), colon cancers ([@bib55]) and prostate cancers ([@bib73]). In contrast, QKI has also been reported to promote tumor formation in both esophageal carcinoma ([@bib30]) and glioblastoma ([@bib61]; [@bib64]). Here, we found that QKI promoted tumor formation in human mammary epithelial cells. These distinct observations may be due to the differences in the initial cell states in which the cancer cells may reside.

The RBFOX1 ORF that we isolated from the screen encodes an isoform (NM_145893.2) that has been previously shown to partially localized to the cytoplasm in neuronal cells ([@bib35]). In breast cells, we observed that 38% of this RBFOX1 isoform (NM_145893.2) localize in the nucleus to regulate pre-mRNA splicing ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). Further studies will be needed to determine whether the cytoplasmic fraction of RBFOX1 also plays an additional role in regulating EMT.

Interestingly, the overexpression of EMT-related TFs such as SNAl1 and ZEB1 induced the QKI*-* and RBFOX1*-*mediated splicing program. Moreover, overexpression of the QKI and RBFOX1 splicing factors themselves promoted a mesenchymal cell state in which SNAI1 and ZEB1 expression were also elevated. These observations indicate that transcriptional and post-transcriptional regulation of EMT complement and regulate one another, suggesting how EMT can be dynamically controlled.

Filamins bind to proteins with diverse functions and important roles in multiple cellular process such as the regulation of cell signaling, transcription and organ development ([@bib75]). In this study, we demonstrated that the skipping of exon 30 in FLNB, which encodes a hinge region (H1), not only serves as a marker for mesenchymal cells but also promotes EMT by releasing the FOXC1 transcription factor from an inhibitory complex. These observations provide a mechanistic explanation of how mesenchymal-specific splicing factors such as QKI and RBFOX1 induce EMT.

Collectively, we conclude that QKI and RBFOX proteins play important roles in establishing the mesenchymal and stem-like cell state in breast cancers, which is in part mediated through their mutual regulation of the skipping of FLNB exon 30. Alternative splicing of pre-mRNAs represents a mechanism for flexibly regulating gene expression by enabling the generation of protein isoforms with distinct or even opposing functions without altering rates of transcription. As such, it offers yet another level of epigenetic control of gene expression. Accordingly, it may provide another means of regulation that tumor cells exploit in order to produce proteins that favor cell survival and cell state changes, such as the EMT programs studied here.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type or resource   Designation                      Source or reference   Identifiers                                                      Additional information
  -------------------------- -------------------------------- --------------------- ---------------------------------------------------------------- ------------------------
  Antibody                   anti-Pan-QKI                     Millipore             MABN624                                                          

  Antibody                   anti-QKI                         Bethyl                A300-183A\                                                       
                                                                                    RRID:[AB_2173160](https://scicrunch.org/resolver/AB_2173160)     

  Antibody                   anti-RBFOX1                      Sigma                 SAB2100002\                                                      
                                                                                    RRID:[AB_10600323](https://scicrunch.org/resolver/AB_10600323)   

  Antibody                   anti-MBNL1                       Santa-Cruz            sc-47740\                                                        
                                                                                    RRID:[AB_784435](https://scicrunch.org/resolver/AB_784435)       

  Antibody                   anti-MBNL2                       Santa-Cruz            sc-136167\                                                       
                                                                                    RRID:[AB_2140469](https://scicrunch.org/resolver/AB_2140469)     

  Antibody                   anti-CELF4(Brunol4)              Santa-Cruz            sc-398292                                                        

  Antibody                   anti-RBFOX2 (RBM9)               Bethyl                A300-864A\                                                       
                                                                                    RRID:[AB_609476](https://scicrunch.org/resolver/AB_609476)       

  Antibody                   anti-FLNB                        Cell signaling        12979S                                                           

  Antibody                   anti-SNAI1                       Cell signaling        3879S\                                                           
                                                                                    RRID:[AB_2255011](https://scicrunch.org/resolver/AB_2255011)     

  Antibody                   anti-Vinculin                    Cell signaling        4650S\                                                           
                                                                                    RRID:[AB_10559207](https://scicrunch.org/resolver/AB_10559207)   

  Antibody                   anti-V5                          Cell signaling        13202                                                            

  Antibody                   anti-V5 (for eCLIP)              Life Technologies     R96025\                                                          
                                                                                    RRID:[AB_159313](https://scicrunch.org/resolver/AB_159313)       

  Antibody                   anti-CD44-PE-Cy7                 Affymetrix            25-0441-81\                                                      
                                                                                    RRID:[AB_469622](https://scicrunch.org/resolver/AB_469622)       

  Chemical compound,\        siRNA NS \#1                     GE Dharmacon          D-001810--01- 05                                                 
  drug                                                                                                                                               

  Chemical compound,\        siFLNB-L1 (3019)                 GE Dharmacon          CTM-237650/\                                                     
  drug                                                                              LJBYN-000019                                                     

  Chemical compound,\        siFLNB-L2 (3021)                 GE Dharmacon          CTM-237646/\                                                     
  drug                                                                              LJBYN-000021                                                     

  Chemical compound,\        siFLNB-S1 (2923)                 GE Dharmacon          CTM-237648/\                                                     
  drug                                                                              LJBYN-000023                                                     

  Chemical compound, drug    siFLNB-S2 (2925)                 GE Dharmacon          CTM-237649/\                                                     
                                                                                    LJBYN-000025                                                     

  Chemical\                  siFOXC1 smart\                   GE Dharmacon          M-009318-01-0005                                                 
  compound, drug             pool of 4 siRNAs                                                                                                        

  Chemical\                  siFLNB-U1\                       GE Dharmacon          CTM-206669                                                       
  compound, drug             (targeting UTR region of FLNB)                                                                                          

  Chemical\                  siFLNB-U2\                       GE Dharmacon          CTM-206671                                                       
  compound, drug             (targeting UTR region of FLNB)                                                                                          

  Chemical\                  Lipofectamine\                   thermofisher          13778150                                                         
  compound, drug             RNAiMAX Transfection\                                                                                                   
                             Reagent                                                                                                                 

  Commercial\                QIAamp DNA Mini Kit              Qiagen                51304                                                            
  assay or kit                                                                                                                                       

  Commercial\                RNeasy Mini kit                  Qiagen                74104                                                            
  assay or kit                                                                                                                                       

  Gene                       QKI                              NCBI Reference        NM_006775.2                                                      

  Gene                       RBFOX1                           NCBI Reference        NM_145893.2                                                      

  Strain,\                   NCr-nude mice                    Taconic               NCRNU,F,\                                                        
  strain background                                                                 CrTac:NCr,Foxn1nu                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s4-1}
------------

The human mammary epithelial (HME) cell line, and its derived cell lines HMLE and HMLER, were grown in Mammary Epithelial Cell Growth Medium (MEGM, Lonza, \#CC-3150). MCF7, BT549, MDAMB231, ZR75-1 cells were grown in Dulbecco's minimum essential medium (DMEM) or Roswell Park Memorial Institute (RPMI) medium containing 10% fetal bovine serum and 1% antibiotics, while 293 T cells were grown in DMEM supplemented with 10% fetal bovine serum and 1% antibiotics. All cell lines were obtained from the Cancer Cell Line Encyclopedia directly from original sources and had their identity confirmed by SNP fingerprinting ([@bib2]). All cells were tested for mycoplasma periodically.

Plasmids and ORFeome library {#s4-2}
----------------------------

The ORFs of EGFP, HcRed, CELF4, MBNL1, MBNL2, QKI, RBFOX1, SFPQ, HNRNPUL1, SRSF9, RBM47, TGFBR2 and SNAI1 were obtained from the Genetic Perturbation Platform at the Broad Institute. Plasmids containing the two isoforms of FLNB (FLNB-L and FLNB-∆H1) were generous gifts from Dr. Arnoud Sonnenberg at the Netherlands Cancer Institute. The ORFeome 8.1 library was produced in the Genetic Perturbation Platform at the Broad Institute. There are the 17,255 ORF clones in the library, among which, 12952 ORF clones have at least 99% nucleotide and protein match (75.1%). Of those genes 7547 ORF clones are 100% protein matches (43.7%) and 6040 are 100% nucleotide matches (35.0%). The construction of the ORF library has been described previously ([@bib66]).

Animal studies {#s4-3}
--------------

All protocols with use of animals were approved by DFCI's Institutional Animal Care and Use Committee (IACUC). For tumor studies, HMLER cells expressing different ORFs were washed and suspended in 50% Matrigel/PBS mix (Corning Matrigel Basement Membrane Matrix, \#354234), then injected subcutaneously in both flanks and in the back of 6-week-old female immunocompromised NCr-nude mice (Taconic, NCRNU-F, CrTac:NCr-Foxn1nu). Two million cells were injected per site. Mice were sacrificed after 15 weeks or when tumors reached a diameter of 2 cm.

Flow cytometry {#s4-4}
--------------

Cells were trypsinized, suspended in phosphate-buffered saline (PBS) with CD44-PE-Cy7 antibody (Affymetrix \# 25-0441-81; 1:500 dilution), and stained for 20 min at room temperature; cells were mixed at 5 min intervals, and then washed with PBS to remove excess antibodies. Immediately after, cells were sorted on a BD FACSAria SORP or analyzed on a BD Fortessa, using BD FACSDiva Software (BD Biosciences, USA).

Mammosphere assay {#s4-5}
-----------------

Mammosphere cultures were generated as described ([@bib11]). Briefly, 1000 cells were seeded per well in a 96-well Corning Ultra-Low attachment plate, in replicates of 6 (Corning, USA; CLS3474). Cells were grown in a serum-free mammary epithelial cell growth medium, supplemented with B27 (Invitrogen), 10 ng/mL EGF, 20 ng/mL bFGF (BD Biosciences) and 1% methycellulose. Bovine pituitary extract was excluded. Spheroid numbers were counted between days 8 and 12 microscopically.

ORF screening {#s4-6}
-------------

The genome-scale screen was performed in two biological replicates. HMLER cells in the CD44-low state were pre-sorted using flow cytometry. The purity of CD44-low cells was \>99.99% for each experiment. HMLER_CD44-low cells were then transduced with the ORF library and cultured for 7 days, with one passage on Day 4. On Day 7, CD44-high cells were sorted from more than 200 million transduced HMLER cells, using flow cytometry for each biological replicate. Sorted CD44-high cells (about 200 thousand cells for each replicate) and their corresponding unsorted HMLER cells were subjected to genomic DNA extraction using the QIAamp DNA Mini Kit (Qiagen \# 51304). The barcodes corresponding to each ORF were amplified using PCR, and analyzed by next-generation sequencing. Enriched barcodes were analyzed as follows: (i) Each sample was normalized to a total of 1 million barcode reads. (ii) The number of each barcode after normalization was calculated to its log base two value. The log value of each barcode in the unsorted group was subtracted from the CD44-high group to obtain the log fold-change in the value of each barcode. (iii) The averages and standard deviations (SD) of the log fold-change values in all samples were determined, and Z scores for each barcode were calculated as follows: Z ~Barcode\ X~= (Log value ~Barcode\ X~ - average)/SD. The Z score was used to evaluate the enrichment of a certain ORF in the CD44-high population, compared with the unsorted population. A higher Z score indicated an enhanced capability for an ORF to promote the conversion of HMLER cells to the CD44-high state.

RNA-sequencing library preparation and data analysis {#s4-7}
----------------------------------------------------

To prepare libraries for RNA sequencing of HME cells that overexpress HcRed, EGFP, QKI, RBFOX1 or SNAI1, we first extracted total RNA using the RNeasy Mini Kit (QIAGEN). Next, 1.5 ug of total RNA was used to generate first strand cDNA using Oligo(dT)12--19 primers (Invitrogen) and AffinityScript Multi-Temp Reverse Transcriptase (Agilent). Second strand cDNA was synthesized using the NEBNext mRNA Second Strand Synthesis Module (NEB) and washed with AMPure XP beads (Beckman Coulter). Finally, libraries were generated from cDNA using the Nextera XT DNA Sample Preparation Kit (Illumina) and Nextera XT Indexes (Illumina). Libraries were pooled and sequenced on the Illumina NextSeq 500 sequencer (paired-end, 150 bp). Image analysis and base calling were done using the standard Illumina pipeline, and then demultiplexed into FASTQ files. Reads were first trimmed using Trimmomatic (version 0.33) to remove Nextera adapter sequences down to a uniform length of 100nt (for compatibility with downstream splicing analysis software). Trimmed reads were then aligned to the human genome (hg19/GRCh37) using STAR (version 2.5.2b) ([@bib20]) and Gencode V19 gene annotations. Alternative splicing was quantified using rMATS (version 3.2.5) ([@bib52]) by comparing each ORF to EGFP, with at least two to three replicates per group. The output from rMATS was further filtered to include only events for which the sum of inclusion counts (IC) and skipping counts (SC) was greater or equal to 10 for both sets of samples.

Alternative splicing quantification across cell lines in CCLE and TCGA breast invasive carcinoma was performed using JuncBASE v.0.8 with default parameters after initial sequence alignment using TopHat v1. To incorporate potentially novel exons, Cufflinks de novo transcript annotations were included from the CCLE data only.

RNA preparation and polymerase chain reaction analysis {#s4-8}
------------------------------------------------------

Total RNA was isolated using the RNeasy Mini kit (Qiagen, 74104) according to the manufacturer's protocol. A cDNA sample, prepared from 1 μg total RNA, was used for quantitative reverse transcription polymerase chain reaction (RT-PCR) performed with the High Capacity cDNA Reverse Transcription Kit (Life Technologies, 4368814) or iScript Reverse Transcription Supermix (BIO-RAD, 1708840). Quantitative PCR (qPCR) was done with the Power SYBR Green Master Mix (Life Technologies; 4368708); data were collected and analyzed on a Bio-Rad Real-Time PCR Detection System or a Roche LightCycler 480 qPCR instrument. Thermal-cycling parameters for the PCR were as follows: 95°C for 10 min, followed by 45 cycles each of 95°C for 20 s, 60°C for 60 s. The relative quantity of mRNA was normalized against the relative quantity of *RPLP0* or *GAPDH* mRNA in the same sample. Primer sequences in a 5′ to 3′ orientation are shown in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

EMT signature analysis for CCLE cell lines and TCGA breast cancer samples {#s4-9}
-------------------------------------------------------------------------

EMT UP and DOWN signatures were derived from previously published datasets based on their pattern of expression relative to the EMT phenotype (TAUBE_EMT_UP/DN, EMT gene set ([@bib55]), GROGER_EMT_UP/DN, EMT gene set ([@bib28]), BYERS_EMT_UP/DN ([@bib9]). The EMT signature scores across CCLE were generated by using the ssGSEA algorithm ([@bib54]). These scores were used to identify the top associated splice targets based on degree of association, an information-theoretic measure Information Coefficient (IC) ([@bib34]). An empirical permutation test was performed for statistical significance calculations.

RNA-sequencing data of TCGA Breast invasive carcinoma (BRCA) samples were downloaded from the GDAC portal of the Broad Institute (<http://gdac.broadinstitute.org/>). The EMT signature scores across TCGA_BRCA samples were generated by the ssGSEA algorithm based on a previously published EMT gene expression signature (CHARAFE_EMT_UP and \_DOWN combined) ([@bib12]; [@bib54]). The top 20% of samples (total n = 1212, mesenchymal tumor = 242) that had the highest EMT scores were counted as mesenchymal tumor samples and the top 20% of samples (n = 242) that had the lowest EMT scores were counted as epithelial tumor samples. The gene expression of EMT markers and RBPs were compared between these mesenchymal and epithelial samples in [Figure 3G](#fig3){ref-type="fig"}. In addition, these scores were used to identify the top correlated gene expression based on degree of association by calculating Pearson Correlation Coefficiency (PCC) and their p values. Breast cancer subtypes were obtained from a PAM50 gene signature-based TCGA analysis ([@bib15]) and correlated with the expression of specific isoforms.

Gene expression analysis for murine mammary tumor gene expression {#s4-10}
-----------------------------------------------------------------

RNA sequencing data for gene expression in primary and recurrent MMTV-HER2 mammary tumors were previously published ([@bib27]). In this model, withdrawal of HER2 expression leads to primary mammary tumor regression but is eventually followed by recurrence of HER2-resistant tumors that harbor a mesenchymal phenotype ([Figure 2---figure supplement 1D--F](#fig2s1){ref-type="fig"}). Ten out of 11 such recurrent tumors underwent EMT as shown by the expression of mesenchymal markers and the spindle-like cellular morphology ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}) ([@bib27]). Strikingly, based on an analysis of the RNA-sequencing results from [@bib27], we found that the expression of Qk (mouse homolog of human QKI) and Rbfox1 were significantly upregulated in the recurring mesenchymal mammary tumors relative to their expression in the corresponding, initially formed epithelial tumors ([Figure 2---figure supplement 1D,E](#fig2s1){ref-type="fig"}). The differential gene expression was evaluated by p values calculated by student's t-test of the normalized expression values between the recurrent tumors and primary tumors. The false discovery rate (FDR) values were generated by comparative marker selection analysis in Genepattern ([@bib48]).

Protein extraction and immunoblotting {#s4-11}
-------------------------------------

Cell extract preparation and immunoblotting were completed as described ([@bib36]). All antibodies used for immunoblotting were listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

For RBFOX1 immunoblotting, we detected a 42 kDa band in HME cell lysate (predicted size). RBFOX1 levels are higher in HMLER cells and we observed a 33 kDa lower band, in addition to the 42 kDa band that corresponds to the predicted size of RBFOX1 ([Figure 2---figure supplement 2C,D](#fig2s2){ref-type="fig"}), which is likely a cleaved form of RBFOX1.

Immunoprecipitation {#s4-12}
-------------------

For preparation of whole cell extract, HME or 293 T cells were harvested, and lysed on ice for 30 min with IP buffer containing 50 mM Tris HCl pH 7.0, 150 mM NaCl, 1 mM EDTA/pH 8, 0.5% Na-deoxycholate, 0.5% NP-40 and 10% glycerol, with protease inhibitors added before use. The lysates were sonicated with 10 pulses on ice, then centrifuged at 14,000 rpm for 5 min, and the supernatants were collected for immunoprecipitation. For preparation of nuclear protein, HMLE nuclear extract was prepared using the Nuclear Complex Co-IP kit (Active Motif \#54001) as described in manufacturer's instructions. Briefly, cell pellets were resuspended in hypotonic buffer to break cell membrane and the nucleus were isolated by centrifugation. The nuclear fraction was further lysed by digestion buffer with enzymatic shearing cocktail before it was further diluted in the IP buffer provided in the kit.

For immunoprecipitations, QKI antibody (Bethyl Laboratories \# A310-050A) or FLNB antibody (Millipore \# AB9276) was added at a concentration of 1 ug per 1 mg of cell lysate, and the lysates were incubated for 2 hr at 4°C; protein A/G agarose was then added and lysates were further incubated for 2 hr at 4°C on a rotator. Protein A/G beads were washed four times in cold IP buffer followed by centrifugation. Samples were boiled in SDS loading buffer, and separated on an SDS-PAGE gel, followed by immunoblotting. For QKI immunoprecipitations, to digest the RBP-associated RNAs, cell lysate was incubated with 50 ng/ml of RNase at room temperature for 20 min before antibodies were added.

siRNA transfection {#s4-13}
------------------

HME, HMLE or HMLER cells were transfected with siRNAs, using Lipofectamine RNAi-MAX. Six hours before the siRNA transfection, cells were split into six-well plates. To prepare transfection complexes, 5 ul of RNAiMAX was mixed into 150 ul of OptiMEM medium in one tube, while 5 ul of 20 mM siRNA was mixed into 150 ul of OptiMEM medium in another tube. Tubes were incubated at room temperature for 20 min before being added to the cells. The cells were harvested 72 hr after transfection.

Immunofluorescence microscopy {#s4-14}
-----------------------------

Immunofluorescence procedures have been described previously ([@bib36]). Briefly, HMLE cells were fixed with cold methanol for 2 min and permeabilized with PBS-1% Triton X-100 for 5 min. Cells were blocked in PBS-donkey serum for 1 hr before being incubated with primary antibody for 2 hr. Alexafluor 488-conjugated donkey anti-rabbit IgG (Invitrogen \# R37118) was used as a secondary antibody. DNA was stained with DAPI. Images were acquired with a Nikon inverted microscope. For Phalloidin staining, cells were fixed with Formalin for 8 min and incubated with Phalloidin-Alexafluor 488 for 1 hr at room temperature before DAPI staining and image analysis.

eCLIP-sequencing library preparation and data analysis {#s4-15}
------------------------------------------------------

RBP-RNA interactions were crosslinked by UV exposure (254 nm, 400 mJ/cm^2^) using a Spectrolinker XL-1500 UV crosslinker. eCLIP was then performed as previously described ([@bib58]) (ENCODE protocol v1.P 20151108) with some minor modifications as follows: (1) immunoprecipitated RNA was 3' end ligated to a custom RNA adapter ('3 SR_RNA'); (2) RNA was released from the nitrocellulose membrane after transfer by treatment with 200 ul of an SDS solution (100 mM Tris, pH 7.5; 50 mM NaCl; 1 mM EDTA; 0.2% SDS) containing 10 ul of proteinase K (Life Technologies, AM2546) and incubating in an Eppendorf thermomixer (60 min at 50°C: 15 s at 1000 r.p.m., 30 s rest), as described in the irCLIP protocol ([@bib72]); (3) reverse transcription was done with a custom RT primer ('SR_RT'); (4) the 3' end of the cDNA was ligated to a custom DNA adapter ('SR_DNA'); (4) amplification of ligated cDNA was done with NEBNext Multiplex Oligos for Illumina (NEB, E7335S); (5) PCR amplified libraries were purified twice with AMPure XP beads (1.0X both times) and then directly quantified by qPCR and run on a Bioanalyzer High Sensitivity DNA chip, before being pooled and submitted for sequencing on the Illumina NextSeq 500 (single-end, 75 bp). For each RBP (QKI and RBFOX1), we prepared and sequenced two replicates and a single size-matched input control derived from the first replicate.

Sequenced reads were processed as previously described ([@bib58]) (ENCODE pipeline v1.P 20160215), with some minor modifications. First, the unique molecular index (UMI) from the 5\' end of each read was extracted using UMI Tools (parameters: umi_tools extract \--bc-pattern=NNNNN). Next, adapters were trimmed using cutadapt (parameters: cutadapt \--match-read-wildcards \--times 1 -e 0.1 -O 1 \--quality-cutoff 6 m 18 -a NNNNAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC). Trimmed reads were first aligned to a database of human repetitive elements (RepBase) using STAR (v2.5.2b) (parameters: STAR \--runMode alignReads \--genomeDir/path/to/RepBase \--readFilesCommand zcat \--outSAMunmapped Within \--outFilterMultimapNmax 30 \--outFilterMultimapScoreRange 1 \--outSAMattributes All \--outStd BAM_Unsorted \--outSAMtype BAM Unsorted \--outFilterType BySJout \--outReadsUnmapped Fastx \--outFilterScoreMin 10 \--outSAMattrRGline ID:foo \--alignEndsType EndToEnd). Reads not mapping to RepBase were then aligned to the human reference genome (hg19 with Gencode V19 annotations) using STAR (v2.5.2b) (parameters: STAR \--runMode alignReads \--genomeDir/path/to/hg19 \--readFilesIn \--outSAMunmapped Within \--outFilterMultimapNmax 1 \--outFilterMultimapScoreRange 1 \--outStd BAM_Unsorted \--outSAMattributes All \--outSAMtype BAM Unsorted \--outFilterType BySJout \--outReadsUnmapped Fastx \--outFilterScoreMin 10 \--outSAMattrRGline ID:foo \--alignEndsType EndToEnd). PCR duplicates were then removed using UMI Tools (parameters: umi_tools dedup \--method directional-adjacency \--spliced-is-unique) leaving only uniquely mapping reads. Finally, CLIP peaks were called using CLIPper software ([@bib38]) and identified peaks were normalized to the appropriate size-matched input control with 'Peak_input_normalization_wrapper.pl' (<https://github.com/YeoLab/gscripts>) before being merged between replicates. Binding motifs were identified using MEME-ChIP ([@bib41]).

Statistics and reproducibility {#s4-16}
------------------------------

All data represent the average of at least three independent experiments, unless otherwise indicated. Significance was calculated by two-tail Student\'s t-test, using GraphPad software. Differences were considered significant when p was \<0.05.

Primer and oligo sequences {#s4-17}
--------------------------

All primer and oligo sequences are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Data availability {#s4-18}
-----------------

Both the RNA-seq data and the CLIP-seq data are deposited at NCBI Gene Expression Omnibus (accession number GSE98210).
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Both the RNA-seq data and the CLIP-seq data are deposited at NCBI Gene Expression Omnibus (accession number GSE98210).

The following dataset was generated:

Choi P2017Alternative splicing regulated by QKI and RBFOX1 promotes the mesenchymal cell state in breast cancer<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98210>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE98210)
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Decision letter

Black

Douglas L

Reviewing Editor

University of California, Los Angeles

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"An alternative splicing switch in FLNB promotes the mesenchymal cell state in breast cancer\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Douglas Black as the Reviewing Editor and James Manley as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study by Li and colleagues examines the role of splicing regulation in driving the epithelial mesenchymal transition (EMT). EMT is a key event in the progression of tumors to a metastatic state and is controlled by an array of genetic mechanisms, including the transcription factors SNAI1, Twist, ZEB1 and others, as well as splicing regulators such as ESRP, RBFOX2 and QKI. The authors previously developed a breast cancer model by transforming mammary epithelial cells with oncogenic factors. The derived cells (HMLER) can be segregated into pre and post EMT populations based on CD44 expression, a marker of metastasis. The CD44 high cells express other mesenchymal markers and exhibit additional properties of these cells, including mammosphere formation. To identify drivers of the transition, the authors infected CD44 low cells with a bar coded cDNA expression library and cells were sorted for CD44 expression. Barcodes enriched in the CD44 high population identified candidates for cDNAs that can induce EMT in HMLER cells. These included the known EMT factor, SNAI1, an indication that other hits in the screen could be similarly important for EMT. These other hits included a preponderance of RNA binding proteins (RBP), two of which, RBFOX1 and QKI, can induce EMT. The authors show that RBFOX1 and QKI alone can increase mesenchymal marker expression and stimulate mammosphere formation. These RBPs are upregulated by SNAI1, and depletion of these proteins by RNAi or CRISPR reduces the effect of SNAI1 on CD44 expression and mammosphere formation. QKI and to a lesser extent RBFOX1 are upregulated in other breast tumors and tumor progression models. Using RNAseq the authors identify changes in splicing induced by QKI and RBFOX1 in their cells and find exons that are coregulated by these RBPs, whose splicing changes are induced by SNAI1. Using CLIP to identify binding sites for QKI and RBFOX1, they show that the proteins bind to sequences adjacent some of the EMT regulated exons making them likely direct targets of QKI and RBFOX1. Focusing on an alternative exon in the actin binding protein Filamin B (FLNB), they show that its skipping correlates with the basal B type of breast cancer. The exon skipped isoform is more active in inducing mesenchymal markers. Using genome editing to force skipping of this exon, they observe modest increases in these markers, in the percent of CD44 high cells, and in mammosphere formation. FLNB was previously shown to bind to the transcription factor FOXC1. Through knockdown experiments the authors show that FOXC1 is needed for the marker expression induced by the RBPs and FLNB.

The reviewers all agreed that his study is a significant contribution to the growing literature on the roles of RBP\'s and posttranscriptional regulation in EMT and tumor progression. Some of the effects are not large, much smaller than SNAI1, leading to questions as to how central these new players are to EMT. Nevertheless, there is a lot of interesting data here, and the experiments are generally well performed and comprehensive. This work will be of broad interest to groups working on both RNA biology and cancer. However, there are a number of issues that need to be addressed before the paper can be considered for publication.

Essential revisions:

1\) There is no characterization of which QKI and RBFOX1 isoforms came out of the screen. Both of these genes produce multiple isoforms, nuclear and cytoplasmic, that have different functions and can cross regulate each other. One cannot assess the true targets of whatever forms were isolated from the library without knowing their structure. Similarly, there needs to be an assessment of whether the endogenous Rbfox or QKI isoforms change with EMT or with ectopic expression of a particular isoform. It appears that the RBFOX1 isoforms could change between HME cells and HMLER cells from the immunoblots in Figure 2---figure supplement 2.

2\) In Figure 2, did the cell proliferation change when the candidate RNA binding proteins were overexpressed? Were there any morphological differences between the CD44-high cells induced by SNAI1 overexpression and those induced by overexpression of QKI or RBFOX1?

3\) RBFOX2 is expressed in a wide variety of cell types and was previously implicated in EMT. In contrast, RBFOX1 is reported to be most abundant in heart, muscle and brain. It is thus important to show validation of the RBFOX1 antibodies, confirming that they do not cross-react with RBFOX2. The isolation of RBFOX1 from an ectopic expression screen is not so surprising, but why was RBFOX2 not isolated? Is it not active for inducing EMT? Given the previous data on RBFOX2 and EMT, it seems surprising that it does not have similar activity.

4\) Many RNA binding proteins co-immunoprecipitate because they bind to common RNAs. The interaction between QKI and RBFOX1 described in Figure 4---figure supplement 1C is not meaningful unless the sample has been treated with RNase.

5\) In Figure 6, the effects of the two FLNB isoforms are relatively small, especially in the CRISPR experiments. It is difficult to draw conclusions from these data, and some of these results appear to be contradictory. In Figure 6C, FLNB-ΔH1 is shown to induce EMT marker expression. But the model in Figure 7 seems to be that the ΔH1 isoform sequesters less of the FOXC1 transcription factor leading to more expression of the EMT markers. If this were true, then over expression of FLNB-L should reduce marker expression and FLNB-ΔH1 should have no effect. The reduction in nuclear FLNB presented in Figure 7---figure supplement 1A is difficult to see and needs to be quantified. The proposed model does not agree with the reported data.

6\) In Figure 6, the protein levels of Filamin B should be shown after siRNA and CRISPR knockdown.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer\" for further consideration at *eLife*. Your revised article has been favorably evaluated by James Manley (Senior Editor) and Reviewing Editor Douglas Black.

In this revised manuscript from Li and colleagues, the authors have added extensive new data and addressed nearly all of the concerns raised by the reviewers. The manuscript is largely ready for publication in *eLife*. However, the editors request that one final point be addressed. The RBFOX1 isoform isolated from the screen and used in the analysis, NM_145893.2, appears to contain the third to last exon (hg38 chr16:7,693,315-7,693,367). Since isoforms containing this exon have been found to be largely localized to the cytoplasm (PMID: 15824060; PMID: 19762510), this raises questions regarding the mechanisms leading to the RBFOX1 dependent splicing change. It is possible that the localization may be different in the system studied here, but this should be confirmed and described. Alternatively, if the RBFOX1 protein driving EMT is cytoplasmic as seen previously, the authors should note this and revise their model in the text.

10.7554/eLife.37184.034

Author response

> Essential revisions:
>
> 1\) There is no characterization of which QKI and RBFOX1 isoforms came out of the screen. Both of these genes produce multiple isoforms, nuclear and cytoplasmic, that have different functions and can cross regulate each other. One cannot assess the true targets of whatever forms were isolated from the library without knowing their structure. Similarly, there needs to be an assessment of whether the endogenous Rbfox or QKI isoforms change with EMT or with ectopic expression of a particular isoform. It appears that the RBFOX1 isoforms could change between HME cells and HMLER cells from the immunoblots in Figure 2---figure supplement 2.

In the open reading frame (ORF) library (human ORFame v8.1, Broad Institute), the ORF encoding QKI is the transcript NM_006775.2 (transcript variant 1, also known as QKI-5). The ORF encoding RBFOX1 is NM_145893.2 (transcript variant 3, also known as RBFOX1 beta). We have included this information in the revised manuscript (subsection "Expression of QKI and RBFOX1 are necessary and sufficient to induce an intermediate mesenchymal cell state", first paragraph).

We agree that some RNA binding proteins such as MBNL1 and RBFOX2 undergo alternative splicing during EMT (Shapiro et al., 2011; Venables et al., 2013). To address whether endogenous QKI undergoes alternative splicing during EMT, we queried the RNA sequencing data that we generated in HME cells in which we expressed SNAI1. We found no significant changes in the distribution of endogenous QKI isoforms (main Refseq transcripts) upon expression of either RBFOX1 or SNAI1 ([Author response image 1A](#respfig1){ref-type="fig"}).

For RBFOX1, we found that our RNA-sequencing data was of insufficient depth to adequately detect RBFOX1 isoform expression and therefore performed RT-PCR to assess alternative N-terminal exons and mutually exclusive exons to detect alternative splicing of internal cassette exons. We found that ectopic expression of QKI or SNAI1 did not result in any significant changes in the exons that we examined ([Author response image 1B](#respfig1){ref-type="fig"}).

![Endogenous QKI and RBFOX1 isoform expression in HME and HMLER cells.\
(**A**) Expression of endogenous QKI isoforms based on RSEM quantification of RNA-sequencing data in HME cells expressing control EGFP, RBFOX1, or SNAI1. (**B**) RT-PCR for alternatively spliced exons in endogenous RBFOX1 in HME cells expressing control EGFP, SNAI1 or QKI. (**C**) Immunoblots for RBFOX1 protein expression in HME or HMLER cells.](elife-37184-resp-fig1){#respfig1}

As noted by the reviewers, we observed a strong smaller RBFOX1 protein band in immunoblotting the HMLER cell lysate compared with the HME cell lysate (previous Figure 2---figure supplement 2). To confirm this finding, we performed a side-by-side comparison of the RBFOX1 proteins in the HME and HMLER cell lysate ([Author response image 1C](#respfig1){ref-type="fig"}). As we found previously, RBFOX1 levels are higher in HMLER cells and showed a stronger 33 kDa lower band, in addition to the 42 kDa band that corresponds to the predicted size of RBFOX1. Through a genetic knockout experiment (see the response to major point \#3), we confirmed that both bands are forms of RBFOX1 ([Author response image 1C](#respfig1){ref-type="fig"} and [Author response image 2A](#respfig2){ref-type="fig"}). Since we failed to detect a shorter mRNA form of RBFOX1 (see above), it is likely that this short form of RBFOX1 was generated through post-translational modifications, possibly through endogenous proteolytic cleavage of RBFOX1 proteins. Using Expasy Peptidecutter tool (web.expasy.org/peptide_cutter/), we found that there are at least 20 proteolytic sites in RBFOX1 that may generate a shorter 33 kDa protein. Further experiments will be needed to determine the identity of the shorter RBFOX1 protein product detected in HMLER cells. We have included a description for RBFOX1 immunoblotting patterns in the revised manuscript (subsection "Protein extraction and immunoblotting").

![Verification of RBFOX1 antibody specificity.\
RBFOX1 (**A**) or RBFOX2 (**B**) was depleted by CRISPR-Cas9-mediated knock out in HMLE cells. RBFOX1 and RBFOX2 proteins were detected by the corresponding antibodies.](elife-37184-resp-fig2){#respfig2}

> 2\) In Figure 2, did the cell proliferation change when the candidate RNA binding proteins were overexpressed? Were there any morphological differences between the CD44-high cells induced by SNAI1 overexpression and those induced by overexpression of QKI or RBFOX1?

In response to the reviewers' question, we overexpressed EGFP, QKI, RBFOX1 and SNAI1 in HME cells and measured cell number after 7 days. We found that overexpression of QKI and RBFOX1 reduced cell proliferation by 40% and 45% respectively, while overexpression of EMT transcription factor SNAI1 decreased cell proliferation by 50%. These observations confirm prior work that showed that initiation of the EMT program slows cell proliferation (Tsai et al., 2012; Vega et al., 2004) and support that notion that expression of QKI and RBFOX1 induces the EMT program. We thank the reviewers for raising this important point and have now included these experiments in Figure 2---figure supplement 3C of the revised manuscript.

The reviewers also asked whether there are morphological differences between the CD44-high cells induced by SNAI1 overexpression and those induced by overexpression of QKI or RBFOX1. To address this question, we sorted for CD44-high HMLER cells induced by QKI, RBFOX1 and SNAI1 expression and stained for phalloidin (marker for F-actin filament) for better visualization of cell morphology. Compared with the control HMLER CD44-low cells, the CD44- high cells induced by QKI, RBFOX1 and SNAI1 all showed similar cell morphologies marked by elongated and spindle shaped cells (revised Figure 2---figure supplement 3A). Thus, despite the relatively lower occurrence of the CD44-high population in QKI- and RBFOX1- expressing cells comparing with SNAI1- expressing cells, the CD44-high cell populations generated by QKI, RBFOX1 or SNAI1 are morphologically similar. We now include these observations in the revised manuscript (Figure 2---figure supplement 3A).

> 3\) RBFOX2 is expressed in a wide variety of cell types and was previously implicated in EMT. In contrast, RBFOX1 is reported to be most abundant in heart, muscle and brain. It is thus important to show validation of the RBFOX1 antibodies, confirming that they do not cross-react with RBFOX2. The isolation of RBFOX1 from an ectopic expression screen is not so surprising, but why was RBFOX2 not isolated? Is it not active for inducing EMT? Given the previous data on RBFOX2 and EMT, it seems surprising that it does not have similar activity.

The reviewers are correct that RBFOX2 has been reported to regulate EMT (Venables et al., 2013; Braeutigam et al., 2014). Unfortunately, the RBFOX2 clone (TRCN0000478244) included in the human ORFome 8.1 (Broad Institute) that we used for the screen harbors three mutations (a 396-449 deletion, a 752-763 deletion and a C to T substitution at 1007), which apparently disrupts the function of RBFOX2 and likely explains why we did not isolate RBFOX2. We have added this information to the revised manuscript (subsection "A genome scale ORF screen to identify regulators of the mesenchymal cell state", last paragraph).

To validate the specificity of the RBFOX1 antibodies, we used CRISPR-Cas9 editing to generate RBFOX1 and RBFOX2 knock-out cells and used them to test the antibody specificity ([Author response image 2](#respfig2){ref-type="fig"}). We found that RBFOX1 antibody (Sigma SAB2100002) recognized a strong band at 42 kDa and a weak band at 33 kDa (see response to major point \#1). The RBFOX2 antibody (Bethyl A300-864A) detected two bands at 52 kDa and 45 KDa (likely to be two splicing isoforms), which were not detected after genetic ablation of the corresponding genes. Therefore, we conclude that the antibodies that we used are specific for RBFOX1.

> 4\) Many RNA binding proteins co-immunoprecipitate because they bind to common RNAs. The interaction between QKI and RBFOX1 described in Figure 4---figure supplement 1C is not meaningful unless the sample has been treated with RNase.

We agree with the reviewers that this is an important specificity control. In response, we incubated the cell lysates with RNase at room temperature for 20 minutes to digest the RNAs before we performed the immunoprecipitation experiment using QKI antibody (revised Figure 4---figure supplement 1C). We found that RNase digestion did not substantially affect the association between QKI and RBFOX1. Therefore, we conclude that the interaction between QKI and RBFOX1 was not mediated through RNAs. We now include this figure in the revised manuscript.

*5) In Figure 6, the effects of the two FLNB isoforms are relatively small, especially in the CRISPR experiments. It is difficult to draw conclusions from these data, and some of these results appear to be contradictory. In Figure 6C, FLNB*-Δ*H1 is shown to induce EMT marker expression. But the model in Figure 7 seems to be that the ΔH1 isoform sequesters less of the FOXC1 transcription factor leading to more expression of the EMT markers. If this were true, then over expression of FLNB-L should reduce marker expression and FLNB-ΔH1 should have no effect. The reduction in nuclear FLNB presented in Figure 7---figure supplement 1A is difficult to see and needs to be quantified. The proposed model does not agree with the reported data.*

We thank the reviewers for raising this important question, which prompted us to further investigate the mechanism by which FLNB alternative splicing regulates EMT. First, to further investigate the function of FLNB-L in regulating EMT, we suppressed FLNB expression by siRNAs in HMLE cells, in which the majority of FLNB protein is the FLNB-L isoform. We found that suppression of FLNB-L upregulated the expression of the mesenchymal markers VIM and FN1, indicating that FLNB-L plays a negative role in regulating EMT (revised Figure 6C), consistent with the model in Figure 7.

Second, we investigated how FLNB-ΔH1 expression increased the expression of mesenchymal markers in the previous Figure 6D. We noted that in the previous Figure 6D, exogenous FLNB isoforms were expressed in the presence of the endogenous proteins. Importantly, it has been demonstrated that filamin proteins dimerize in cells (Berry et al., 2005; Pudas et al., 2005; Stossel et al., 2001). Therefore, it is possible that the exogenous FLNB-ΔH1 dimerized with the endogenous FLNB-L and affected the function of endogenous FLNB-L. Specifically, overexpression of FLNB-ΔH1 may promote the release of the nuclear FOXC1 by dimerizing with the endogenous FLNB-L. To test this possibility, we suppressed the endogenous FLNB using 2 siRNAs targeting the 3'UTR region of FLNB and rescued the FLNB expression by overexpression of two different FLNB isoforms (revised Figure 6D). Depletion of endogenous FLNB-L consistently promoted mesenchymal marker expression (Lane 2 from the left). In the context of endogenous FLNB suppression, FLNB-L expression reduced the expression of mesenchymal markers, FN1 and VIM (Lane 2, 3). In contrast, the expression of FLNB-ΔH1 did not decrease the mesenchymal marker expression (Lane 2-4). Taken together, these observations strongly suggest that FLNB-L plays a negative role in promoting EMT.

Third, as indicated by the reviewers and the new experiments that we described above, we expected to see a reduction of mesenchymal markers upon FLNB-L expression in mesenchymal cells. However, the cell line that we used in Figure 6C and D was human mammary epithelial cells (HMLE), which reside in an epithelial cell state. The effect of FLNB-L overexpression was not likely to make them even more epithelial. To further test this hypothesis, we overexpressed FLNB-L and FLNB-ΔH1 in a breast cancer cell line that exhibits the mesenchymal state, MDA-MD-231, and examined the expression of mesenchymal markers (new Figure 6---figure supplement 1A). We found that overexpression of FLNB-L in this mesenchymal cell line indeed reduced the expression of mesenchymal markers. Again, the expression of FLNB-ΔH1 did not seem to significantly further increase VIM expression probably because MDA-MD-231 cells are already in a mesenchymal state.

We thank the reviewers for prompting us to extend our understanding of the mechanism by which FLNB alternative splicing regulates EMT. We now include the new experiments and discussion in the revised manuscript (Figure 6C, D and Figure 6---figure supplement 1A, subsection "FLNB isoform switching promotes a mesenchymal - like cell state", second paragraph). We also include the quantification of FLNB nuclear intensity in the revised Figure 7---figure supplement 1A (right).

> 6\) In Figure 6, the protein levels of Filamin B should be shown after siRNA and CRISPR knockdown.

We now provide the immunoblots for Filamin B in the revised Figure 6F (bottom) and revised Figure 6---figure supplement 1D where we assess Filamin B protein levels after CRISPR- or siRNA-mediated change of the endogenous ratios of the two FLNB isoforms (FLNB-L and FLNB-ΔH1). Specifically, we performed two experiments. In the first experiment, we used CRISPR-mediated editing of the splicing junction of the genomic locus and found a minor reduction of the endogenous FLNB proteins. We also performed a second experiment in which we used siRNA-mediated suppression of a specific mRNA isoforms and found a significant reduction of the total FLNB proteins, indicating that the siRNA approach has a more profound impact on the total protein levels. In both methods, the ratio of the endogenous FLNB isoforms changed substantially.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> In this revised manuscript from Li and colleagues, the authors have added extensive new data and addressed nearly all of the concerns raised by the reviewers. The manuscript is largely ready for publication in eLife. However, the editors request that one final point be addressed. The RBFOX1 isoform isolated from the screen and used in the analysis, NM_145893.2, appears to contain the third to last exon (hg38 chr16:7,693,315-7,693,367). Since isoforms containing this exon have been found to be largely localized to the cytoplasm (PMID: 15824060; PMID: 19762510), this raises questions regarding the mechanisms leading to the RBFOX1 dependent splicing change. It is possible that the localization may be different in the system studied here, but this should be confirmed and described. Alternatively, if the RBFOX1 protein driving EMT is cytoplasmic as seen previously, the authors should note this and revise their model in the text.

To determine the subcellular localization of this RBFOX1 isoform (NM_145893.2), we performed immunofluorescence for the RBFOX1 ORF that we used in these experiments (v5 tagged). In consonance with the prior report in neuronal cells \[Figure 2, (Lee et al., 2009)\], we found that the 62% of this protein isoform localized to the cytoplasm in human mammary epithelial cells. Meanwhile, 38% of RBFOX1 localizes to the nucleus (revised Figure 7---figure supplement 1D). This observation confirms that a substantial fraction of this RBFOX1 isoform is in the nucleus. In addition, our eCLIP data (Figure 4 in the manuscript) also suggested that a portion of the RBFOX1 isoform studied here binds to specific mRNAs. Therefore, although it remains possible that the cytoplasmic fraction of RBFOX1 may also contribute to EMT, the nuclear fraction of this RBFOX1 isoform likely plays an important role in regulating EMT-related pre-mRNA splicing. We have included a paragraph in the revised manuscript (Discussion, fourth paragraph; Figure 7---figure supplement 1D) to discuss this observation. We thank the editor for raising this important point.

[^1]: These authors contributed equally to this work.
